CareDx, Inc. (CDNA)

In the past six months, CareDx's stock has experienced several significant events. CareDx announced strong first-quarter 2026 financial results, with total revenue increasing 39% year-over-year and raised its full-year 2026 revenue guidance. CareDx entered into a definitive agreement to acquire Naveris, Inc. CareDx announced an agreement to divest its Lab Products business to EuroBio Scientific. The Board authorized a new common stock repurchase program of up to $100 million over 24 months. CEO John Walter Hanna, Jr. sold 10,282 shares of the company's stock. Wall Street Zen upgraded CareDx (CDNA) from a "buy" to a "strong-buy."

CareDx's business experiences some demand seasonality, particularly in its testing volumes. The company anticipates a step-up in testing volume from Q1 to Q2, remaining flat from Q2 to Q3, and another step-up in volume from Q3 to Q4. The second and fourth quarters typically see increased demand for its testing services.

CareDx, Inc. is a precision medicine company focused on improving outcomes for transplant patients. It operates in the medical laboratories industry, providing clinically differentiated healthcare solutions for transplant patients and caregivers. The company's products and services include non-invasive molecular testing, laboratory products, and digital health solutions such as AlloSure Kidney, AlloMap Heart, and Ottr.

CareDx, Inc. is headquartered in Brisbane, California, which serves as its central hub. The company generates the majority of its revenue from the United States. CareDx also has a European office and laboratory in Stockholm, Sweden, which functions as a regional center for the EMEA market. Additionally, CareDx operates other sites that support its global operations and employs remote and field-based professionals across various functions worldwide.

CareDx positions itself as "The Transplant Company" and a leader in precision medicine for transplant patients. The company's brand reputation is built on its commitment to improving outcomes for transplant recipients and advancing organ health through innovative diagnostic solutions. CareDx has continued to highlight its scientific contributions. However, the company has faced some scrutiny regarding its AlloSure test and potential Medicare reimbursement changes.

CareDx, Inc. has a diversified ownership landscape, with institutional investors holding a significant portion of the company. As of May 5, 2026, there were 198 institutional owners holding a total of 52,285,608 shares. Institutional investors hold approximately 49.54% of the shares, while insiders own about 9.42%, and public companies and individual investors hold the remaining 41.04%. Major institutional owners include BlackRock, Inc. and Vanguard Group Inc. Neil Gagnon is noted as a significant individual shareholder.